The current stock price of IRTC is 171.66 USD. In the past month the price decreased by -1.35%. In the past year, price increased by 85.18%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.12 | 217.98B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.33 | 199.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.53 | 142.24B | ||
| SYK | STRYKER CORP | 26.92 | 135.57B | ||
| BDX | BECTON DICKINSON AND CO | 13.5 | 55.57B | ||
| IDXX | IDEXX LABORATORIES INC | 55.8 | 56.18B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.21 | 49.53B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.99 | 37.61B | ||
| RMD | RESMED INC | 24.48 | 35.38B | ||
| DXCM | DEXCOM INC | 35.41 | 25.69B | ||
| PODD | INSULET CORP | 64.75 | 20.82B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.25 | 18.03B |
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. The company is headquartered in San Francisco, California and currently employs 2,000 full-time employees. The company went IPO on 2016-10-20. The firm designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. The company offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. The company offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
IRHYTHM TECHNOLOGIES INC
699 8th Street, Suite 600
San Francisco CALIFORNIA 94103 US
CEO: Michael Coyle
Employees: 2000
Phone: 14156325700
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. The company is headquartered in San Francisco, California and currently employs 2,000 full-time employees. The company went IPO on 2016-10-20. The firm designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. The company offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. The company offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
The current stock price of IRTC is 171.66 USD. The price increased by 2.56% in the last trading session.
IRTC does not pay a dividend.
IRTC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IRTC.
IRHYTHM TECHNOLOGIES INC (IRTC) currently has 2000 employees.
IRHYTHM TECHNOLOGIES INC (IRTC) will report earnings on 2026-02-18, after the market close.
ChartMill assigns a technical rating of 5 / 10 to IRTC. When comparing the yearly performance of all stocks, IRTC is one of the better performing stocks in the market, outperforming 91.95% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to IRTC. The financial health of IRTC is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months IRTC reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS increased by 69.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.17% | ||
| ROE | -42.22% | ||
| Debt/Equity | 5.32 |
22 analysts have analysed IRTC and the average price target is 225.01 USD. This implies a price increase of 31.08% is expected in the next year compared to the current price of 171.66.
For the next year, analysts expect an EPS growth of 59.19% and a revenue growth 26.1% for IRTC